In this issue:
QuiRedex: survival benefit to early treatment for high-risk smoldering myeloma
Second revision of the ISS for overall survival in MM
CTCs for the staging of newly diagnosed transplant-eligible myeloma
High level of CTCs is prognostic for aggressive myeloma
E-KRd induction efficacious for newly diagnosed MM
Standard-of-care regimens for newly diagnosed MM vary widely across Europe
Obesity is associated with increased risk for myeloma
A GPRC5D-targeted CAR T cell demonstrates activity in RRMM
Development of second-generation anti-BCMA CAR variants
PCL-like status represents high-risk disease in newly diagnosed myeloma
Please login below to download this issue (PDF)